Study Summary
This trial tests how well a drug, LY3502970, is absorbed and eliminated in overweight and obese patients and if it's safe and tolerated. It also looks at how food affects it. 135 days total.
- Healthy Subjects
- Obesity
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
3 Primary · 3 Secondary · Reporting Duration: Predose up to 92 days postdose
Trial Safety
Phase-Based Safety
Awards & Highlights
Trial Design
2 Treatment Groups
LY3502970 (Part B)
1 of 2
LY3502970 (Part A)
1 of 2
Experimental Treatment
50 Total Participants · 2 Treatment Groups
Primary Treatment: LY3502970 (Part B) · No Placebo Group · Phase 1
Trial Logistics
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18 - 70 · All Participants · 3 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Does the experimental program accept individuals below the age of sixty-five?
"According to the eligibility requirements of this trial, individuals between 18 and 70 are considered fit for participation. For those under eighteen or over 65 years old there are 114 studies available while 574 can be found respectively." - Anonymous Online Contributor
Are there still enrollment opportunities in this research endeavor?
"As evidenced on clinicaltrials.gov, the recruitment phase of this study has concluded; it was initially posted to the website on April 27th 2023 and last updated 24 days later. Although there are no longer any vacancies for this particular trial, 1144 other medical studies have open positions available at present." - Anonymous Online Contributor
Are there any limitations on who may participate in this experiment?
"To qualify for this research initiative, volunteers must be in good health and between the ages of 18-70. Approximately 50 individuals are needed to fulfill the trial's requirements." - Anonymous Online Contributor
What safety data is available for LY3502970 (Part A) in clinical trials?
"Due to the minimal amount of information available on LY3502970 (Part A), our team at Power have given it a safety rating of 1. This is because this trial is only in Phase 1, thus there are limited results regarding its efficacy and safety profile." - Anonymous Online Contributor